US FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co
US FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co
- HCV co-infection remains a major cause of morbidity in HIV-infected individuals. With this expanded use, Epclusa provides co-infected patients with a ...
- HCV co-infection remains a major cause of morbidity in HIV-infected individuals. With this expanded use, Epclusa provides co-infected patients with a ...